StockMacro
Menu

Caris Life Sciences

$17.58 +13% in 6 monthsMarket cap $5.0B

CAI on XNAS, Health Care, Caris Life Sciences, Inc., job postings

Measures activity, not value. Not investment advice.

Shares down 46% in one month even as quarterly revenue rose 27% and insiders sold $27.2M in 90 days.

  • GoodTwelve-month revenue up 61% to $1B with net profit of $96.1M
  • GoodInstitutional holders rose 33% to 324 in the latest quarter

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

Industry
Services-medical laboratories (Health Care)
Employees
1,846
Website
carislifesciences.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $275.4M, net income $15.2M.
Quarter to 30 Jun 2024: revenue $100.0M, net income -$66.2MQuarter to 30 Jun 2024: revenue $100.0M, net income -$66.2MQuarter to 30 Sep 2024: revenue $101.6M, net income -$67.7MQuarter to 30 Sep 2024: revenue $101.6M, net income -$67.7MQuarter to 31 Dec 2024: revenue $129.9M, net income -$36.9MQuarter to 31 Dec 2024: revenue $129.9M, net income -$36.9MQuarter to 31 Mar 2025: revenue $120.9M, net income -$102.6MQuarter to 31 Mar 2025: revenue $120.9M, net income -$102.6MQuarter to 30 Jun 2025: revenue $181.4M, net income -$71.8MQuarter to 30 Jun 2025: revenue $181.4M, net income -$71.8MQuarter to 30 Sep 2025: revenue $216.8M, net income $24.3MQuarter to 30 Sep 2025: revenue $216.8M, net income $24.3MQuarter to 31 Dec 2025: revenue $292.9M, net income $82.0MQuarter to 31 Dec 2025: revenue $292.9M, net income $82.0MQuarter to 31 Mar 2026: revenue $216.2M, net income -$510KQuarter to 31 Mar 2026: revenue $216.2M, net income -$510KQuarter to 30 Jun 2026: revenue $263.7M, net income -$637KQuarter to 30 Jun 2026: revenue $263.7M, net income -$637KQuarter to 30 Sep 2026: revenue $275.4M, net income $15.2MQuarter to 30 Sep 2026: revenue $275.4M, net income $15.2M
30 Jun 2024RevenueNet incomeNet losstallest bar $292.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$275.4M$15.2M
30 Jun 2026$263.7M-$637K
31 Mar 2026$216.2M-$510K
31 Dec 2025$292.9M$82.0M
30 Sep 2025$216.8M$24.3M
30 Jun 2025$181.4M-$71.8M
31 Mar 2025$120.9M-$102.6M
31 Dec 2024$129.9M-$36.9M
30 Sep 2024$101.6M-$67.7M
30 Jun 2024$100.0M-$66.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.0B $649.1M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +61% +17%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $96.1M -$187.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 33.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 13.4% -12.4% -8.2%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 9.2% -28.8% -5.9%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 17.2% -10.1%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$14.0M
CashCash, cash equivalents and short-term investments on the latest balance sheet. – $755.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $393.3M $376.5M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – -$379.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.61 0.16
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $2.23
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 52.5 29.1
P/SPrice to sales: market cap divided by revenue of the last 12 months. 4.8 3.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 2.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 7.9 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Caris Life SciencesCAI (this company) $5.0B52.54.8+61%9.2%
RadNetRDNT $5.5Bloss2.3+21%-0.9%
GRAILGRAL $4.5Bloss26.8+17%-244%
BillionToOneBLLN $4.3B87.09.8+72%11.3%
CareDxCDNA $3.7B28.67.4+39%25.9%
CelcuityCELC $2.6Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$27.2M

bought $0, sold $27.2M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+33%

324 13F filers vs 243

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

54%

154.9M shares held by 13F filers (30 Sep 2026) of 286.8M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.0%

11.5M shares sold short (30 Oct 2026) of 286.8M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.0

11.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-15%

13.6M shares sold short in the report before, 11.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

35%

35% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+27%

$275.4M vs $216.8M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+146%

$17.5M vs $7.1M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$280K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

2.2×

11 articles in the last 7 days; its usual week has 5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Lobbying spend $160K, 4.0× a year earlier
  • Capital spending $17.5M, 2.5× a year earlier

Price $17.58 on 20 Nov 2026, -27% over 12 months (12-month range $14.55 to $36.14)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $27.4M in the last 12 months (the 12 months before: $898K).
Revenue per quarter. Revenue $275.4M in the latest quarter, +27% on a year earlier.
Capital spending per quarter. Capital spending $17.5M in the latest quarter, +146% on a year earlier.
Institutional holders (13F filers). 324 13F filers reported holding it in the latest 13F quarter, +142% on a year earlier.
Lobbying spend. Lobbying spend: $280K published in the last 12 months, +75% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
5 Nov 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 17.5M vs usual 3.9M (2026-09-30); 2.5x the same period a year earlier
27 Oct 2026Sharp changeLobbying spend jump: lobbying spend jump, 160K vs usual 40K (2026-09-30); 4.0x the same period a year earlier
6 Aug 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 22.1M vs usual 2.7M (2026-06-30); 15.9x the same period a year earlier
12 May 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 10.3M vs usual 2.5M (2026-03-31); 3.8x the same period a year earlier
2 Apr 20268-K and other filingsA major agreement ended
16 Jun 20258-K and other filingsRegistered new securities for sale (S-1)
9 Jun 20258-K and other filingsRegistered new securities for sale (S-1)
23 May 20258-K and other filingsRegistered new securities for sale (S-1)
Insider net buying (open market)
Month from 1 Jun 2025: $788K published
Month from 1 Nov 2025: $110K published
Month from 1 Dec 2025: -$1.7M published
Month from 1 May 2026: $501K published
Month from 1 Jul 2026: $990K published
Month from 1 Sep 2026: -$27.2M published
Revenue per quarter
Quarter ended 30 Jun 2024: $100.0M; public on 13 Aug 2025
Quarter ended 30 Sep 2024: $101.6M; public on 6 Nov 2025
Quarter ended 31 Dec 2024: $129.9M; public on 4 Mar 2026
Quarter ended 31 Mar 2025: $120.9M; public on 9 May 2026
Quarter ended 30 Jun 2025: $181.4M, +81% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $216.8M, +113% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $292.9M, +125% on a year earlier; public on 4 Mar 2026
Quarter ended 31 Mar 2026: $216.2M, +79% on a year earlier; public on 9 May 2026
Quarter ended 30 Jun 2026: $263.7M, +45% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $275.4M, +27% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 30 Sep 2024: $1.8M; public on 6 Nov 2025
Quarter ended 31 Dec 2024: $2.3M; public on 4 Mar 2026
Quarter ended 31 Mar 2025: $2.7M; public on 9 May 2026
Quarter ended 30 Jun 2025: $1.4M; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $7.1M, +288% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $5.1M, +122% on a year earlier; public on 4 Mar 2026
Quarter ended 31 Mar 2026: $10.3M, +285% on a year earlier; public on 9 May 2026
Quarter ended 30 Sep 2026: $17.5M, +146% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
30 Jun 2025 report: 113; public on 14 Aug 2025
30 Sep 2025 report: 134; public on 14 Nov 2025
31 Dec 2025 report: 183; public on 17 Feb 2026
31 Mar 2026 report: 195; public on 15 May 2026
30 Jun 2026 report: 243; public on 14 Aug 2026
30 Sep 2026 report: 324; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $40K published
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Jul 2022: $40K published
Quarter from 1 Oct 2022: $40K published
Quarter from 1 Jan 2023: $40K published
Quarter from 1 Apr 2023: $40K published
Quarter from 1 Jul 2023: $40K published
Quarter from 1 Oct 2023: $40K published
Quarter from 1 Jan 2024: $40K published
Quarter from 1 Apr 2024: $40K published
Quarter from 1 Jul 2024: $40K published
Quarter from 1 Oct 2024: $40K published
Quarter from 1 Jan 2025: $40K published
Quarter from 1 Apr 2025: $40K published
Quarter from 1 Jul 2025: $40K published
Quarter from 1 Oct 2025: $40K published
Quarter from 1 Jan 2026: $40K published
Quarter from 1 Apr 2026: $40K published
Quarter from 1 Jul 2026: $40K published
Quarter from 1 Oct 2026: $160K published

What is unusual now

  • Made public in the last 90 days: it reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year; it also spent $17.5M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year. Two or more unrelated kinds of activity agreed on 5 Nov 2026.
  • Quarterly capital spending jump: spent $22.1M on capital projects in the quarter ended 30 Jun 2026, 16× the same quarter last year Public on 6 Aug 2026.
  • Lobbying spend jump: reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year Public on 21 Oct 2026.
  • Insider net buying (open market): Insiders sold a net $27.4M in the last 12 months (the 12 months before: $898K).

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 10 insider trades

Last 90 days: 3 sales, $27.2M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
23 Sep 2026John Russel DentonSee RemarksSell7,500$31.82$239KForm 4
17 Sep 2026Brian J BrilleSee RemarksSellafter exercising options400,000$30.33$12.1MForm 4
4 Sep 2026David Baxley SpetzlerPresidentSellafter exercising options597,212$24.84$14.8MForm 4
13 Jul 2026Jon HalbertDirectorBuy68,000$14.56$990KForm 4
12 May 2026Jeff L VacircaDirectorBuy31,050$16.15$501KForm 4
12 Dec 2025Luke Thomas PowerSee RemarksSellplanned in advance (10b5-1); after exercising options62,250$26.57$1.7MForm 4
10 Nov 2025David Baxley SpetzlerPresidentBuy400$23.85$10KForm 4
10 Nov 2025John Russel DentonSee RemarksBuy4,184$24.09$101KForm 4

324 institutions reported shares at the end of Q3 2026, 54% of the shares outstanding; 114 opened a position, 38 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)38.3M13.4%$1.2B+7.4M+24%
AQR Capital Management LLC8.2M2.86%$251.5M+8.2M139 times as many
BlackRock, Inc.7.9M2.74%$240.9M+2.3M+42%
D. E. Shaw & Co., Inc.7.2M2.52%$221.1M+7.0M35 times as many
Vanguard Capital Management LLC5.7M2.00%$175.6M+1.5M+34%
T. Rowe Price Associates Inc4.8M1.68%+3.6M+299%
Vanguard Portfolio Management LLC4.7M1.65%$144.9M-114K-2.4%
Capital World Investors4.4M1.53%$134.4M+3.2M+262%
BNP Paribas Financial Markets3.5M1.22%$107.6M+1.1M+48%
JPMorgan Chase & Co3.4M1.20%$108.7M-3.1M-48%

Company events

All 5 company events

In 12 months: 1 major agreement, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
2 Apr 2026Signed a major agreement; A major agreement endedSame filing: took on new debt8-K
16 Jun 2025Registered new securities for sale (S-1)S-1/A
9 Jun 2025Registered new securities for sale (S-1)S-1/A
23 May 2025Registered new securities for sale (S-1)S-1

Reported lobbying spend: $160K in Q3 2026, $40K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
19 Sep 2017NewSplitoak Strategies LLCfor Caris Life Sciences, Inc.Coverage and reimbursement of Next Generation Sequencing and other precision medicine technologies. Date of Service requirements, PAMA implementing regulations reforming clinical lab payment policy.MED, Medicare/Medicaid, Health issuesFiling
20 Jun 2014EndedThe Mcmanus Groupfor Caris Life Sciences, Inc.Advanced molecular diagnostic policy. Laboratory and pathology coverage and payment issues.Health issuesFiling
20 Jun 2014EndedCaris Life Sciences, Inc.its own lobbyistsPatient Protection and Affordable Care Act (PPACA) implementation issues; Budget Control Act of 2011; Sustainable Growth Rate reform; Medicare reimbursement and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2014 Medicare Budget proposals; Implementation of the Protect; Patient Protection and Affordable Care Act (PPACA) implementation issues; Coverage and pricing policies for molecular diagnostic cancer tests; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures Initiative.; Sustainable Growth Rate reform; Clinical lab and physician fee schedule reforms and beneficiary cost sharing proposals; President Obama's FY2014 Medicare Budget proposals; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures Initiative.; Patient Protection and Affordable Care Act (PPACA) implementation issues; Medicare reimbursement and beneficiary cost-sharing for Clinical Lab Fee Schedule; President Obama's FY2014 Medicare Budget proposals; Implementation of the Protecting Access to Medicare Act of 2014; 21st Century Cures InitiatMED, Insurance, Medicare/Medicaid, Health issuesFiling
15 Feb 2014NewThe Mcmanus Groupfor Caris Life Sciences, Inc.Advanced molecular diagnostic policy. Laboratory and pathology coverage and payment issues.Health issuesFiling
21 Mar 2011NewCaris Life Sciences, Inc.its own lobbyistsReimbursement issues for lab-developed tests, self-referral legislation, FDA regulatory issues, health care reformHealth issues, Medicare/Medicaid, Insurance, MEDFiling

The 5 newest of 190 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

5 Nov 2026confirmed

Confirmed across sources Filings + Financials and Lobbying

Caris Life Sciences (CAI): reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year, while it spent $17.5M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year. Two unrelated kinds of activity within 9 days.

  • Lobbying: Lobbying spend jump, became public on 21 Oct 2026
  • Financials: Quarterly capital spending jump, became public on 5 Nov 2026
2024-09-30: $40K2024-12-31: $40K2025-03-31: $40K2025-06-30: $40K2025-09-30: $40K2025-12-31: $40K2026-03-31: $40K2026-06-30: $40K2026-09-30: $160K
The quarter ended 30 Sep 2026 against the 8 quarters before it. this quarterearliernormal: $40K
See the evidence (2 changes)

Lobbying: Lobbying spend jump became public on 21 Oct 2026

Caris Life Sciences reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year.

This period
$160K (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$40K
Typical spread (median absolute deviation)
$0
How far from its usual level
+6.0
Same quarter last year
$40K
History used
5,662 days
2024-09-30: $40K2024-12-31: $40K2025-03-31: $40K2025-06-30: $40K2025-09-30: $40K2025-12-31: $40K2026-03-31: $40K2026-06-30: $40K2026-09-30: $160K
the quarter ended 30 Sep 20268 earlier quartersnormal: $40K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

Check it at the source: Senate/House lobbying disclosures (LDA).

Financials: Quarterly capital spending jump became public on 5 Nov 2026

Caris Life Sciences spent $17.5M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year.

This period
$17.5M (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$3.9M
Typical spread (median absolute deviation)
$2.3M
How far from its usual level
+4.0
Same quarter last year
$7.1M
History used
730 days
2024-09-30: $1.8M2024-12-31: $2.3M2025-03-31: $2.7M2025-06-30: $1.4M2025-09-30: $7.1M2025-12-31: $5.1M2026-03-31: $10.3M2026-06-30: $22.1M2026-09-30: $17.5M
the quarter ended 30 Sep 20268 earlier quartersnormal: $3.9M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 5 Nov 2026several at once

    reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year, while it spent $17.5M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year. Two unrelated kinds of activity within 9 days.

    See the evidence (2 changes)

    Lobbying: Lobbying spend jump became public on 21 Oct 2026

    Caris Life Sciences reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year.

    This period
    $160K (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $40K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +6.0
    Same quarter last year
    $40K
    History used
    5,662 days
    2024-09-30: $40K2024-12-31: $40K2025-03-31: $40K2025-06-30: $40K2025-09-30: $40K2025-12-31: $40K2026-03-31: $40K2026-06-30: $40K2026-09-30: $160K
    the quarter ended 30 Sep 20268 earlier quartersnormal: $40K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

    Financials: Quarterly capital spending jump became public on 5 Nov 2026

    Caris Life Sciences spent $17.5M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year.

    This period
    $17.5M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $3.9M
    Typical spread (median absolute deviation)
    $2.3M
    How far from its usual level
    +4.0
    Same quarter last year
    $7.1M
    History used
    730 days
    2024-09-30: $1.8M2024-12-31: $2.3M2025-03-31: $2.7M2025-06-30: $1.4M2025-09-30: $7.1M2025-12-31: $5.1M2026-03-31: $10.3M2026-06-30: $22.1M2026-09-30: $17.5M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $3.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  2. 5 Nov 2026Financials change

    spent $17.5M on capital projects in the quarter ended 30 Sep 2026, 2.5× the same quarter last year.

    Same quarter last year: $7.1M; its normal quarter is $3.9M.

    See the evidence
    This period
    $17.5M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $3.9M
    Typical spread (median absolute deviation)
    $2.3M
    How far from its usual level
    +4.0
    Same quarter last year
    $7.1M
    History used
    730 days
    2024-09-30: $1.8M2024-12-31: $2.3M2025-03-31: $2.7M2025-06-30: $1.4M2025-09-30: $7.1M2025-12-31: $5.1M2026-03-31: $10.3M2026-06-30: $22.1M2026-09-30: $17.5M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $3.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  3. 21 Oct 2026Lobbying change

    reported $160K of lobbying spend for the quarter ended 30 Sep 2026, 4.0× the same quarter last year.

    Same quarter last year: $40K; its normal quarter is $40K.

    See the evidence
    This period
    $160K (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $40K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +6.0
    Same quarter last year
    $40K
    History used
    5,662 days
    2024-09-30: $40K2024-12-31: $40K2025-03-31: $40K2025-06-30: $40K2025-09-30: $40K2025-12-31: $40K2026-03-31: $40K2026-06-30: $40K2026-09-30: $160K
    the quarter ended 30 Sep 20268 earlier quartersnormal: $40K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  4. 6 Aug 2026Financials change

    spent $22.1M on capital projects in the quarter ended 30 Jun 2026, 16× the same quarter last year.

    Same quarter last year: $1.4M; its normal quarter is $2.7M.

    See the evidence
    This period
    $22.1M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 7 earlier)
    $2.7M
    Typical spread (median absolute deviation)
    $1.3M
    How far from its usual level
    +10.0
    Same quarter last year
    $1.4M
    History used
    638 days
    2024-09-30: $1.8M2024-12-31: $2.3M2025-03-31: $2.7M2025-06-30: $1.4M2025-09-30: $7.1M2025-12-31: $5.1M2026-03-31: $10.3M2026-06-30: $22.1M
    the quarter ended 30 Jun 20267 earlier quartersnormal: $2.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  5. 14 Jul 2026Insiders record

    HALBERT JON (director) bought 68,000 shares of CAI ($990,080) (dated 13 Jul 2026)

  6. 13 May 2026Insiders record

    Vacirca Jeff L (director) bought 31,050 shares of CAI ($501,458) (dated 12 May 2026)

  7. 12 May 2026Financials change

    spent $10.3M on capital projects in the quarter ended 31 Mar 2026, 3.8× the same quarter last year.

    Same quarter last year: $2.7M; its normal quarter is $2.5M.

    See the evidence
    This period
    $10.3M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 6 earlier)
    $2.5M
    Typical spread (median absolute deviation)
    $882K
    How far from its usual level
    +6.0
    Same quarter last year
    $2.7M
    History used
    547 days
    2024-09-30: $1.8M2024-12-31: $2.3M2025-03-31: $2.7M2025-06-30: $1.4M2025-09-30: $7.1M2025-12-31: $5.1M2026-03-31: $10.3M
    the quarter ended 31 Mar 20266 earlier quartersnormal: $2.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  8. 2 Apr 2026Filings record

    A major agreement ended

  9. 11 Nov 2025Insiders record

    Spetzler David Baxley (President) bought 400 shares of CAI ($9,540) (dated 10 Nov 2025)

  10. 11 Nov 2025Insiders record

    Denton John Russel (See Remarks) bought 4,184 shares of CAI ($100,793) (dated 10 Nov 2025)

  11. 14 Aug 2025Institutional holdings record

    COATUE MANAGEMENT LLC opened a $271.0M position (2025Q2 13F)

  12. 24 Jun 2025Insiders record

    Brille Brian J (See Remarks) bought 30,000 shares of CAI ($630,000) (dated 23 Jun 2025)

  13. 24 Jun 2025Insiders record

    Denton John Russel (See Remarks) bought 7,500 shares of CAI ($157,500) (dated 23 Jun 2025)

  14. 16 Jun 2025Filings record

    Registered new securities for sale (S-1)

  15. 9 Jun 2025Filings record

    Registered new securities for sale (S-1)

  16. 23 May 2025Filings record

    Registered new securities for sale (S-1)

  17. 27 Jul 2021Short interest and volume change

    had 600K shares sold short in the 15 Jul 2021 report, 1.5× the same report last year.

    Same report last year: 397K; its normal report is 298K.

    See the evidence
    This period
    600K (the 15 Jul 2021 report)
    Normal report (median of 24 earlier)
    298K
    Typical spread (median absolute deviation)
    48K
    How far from its usual level
    +4.3
    Same report last year
    397K
    History used
    1,294 days
    2020-07-15: 397K2020-07-31: 354K2020-08-14: 305K2020-08-31: 285K2020-09-15: 259K2020-09-30: 191K2020-10-15: 368K2020-10-30: 374K2020-11-13: 348K2020-11-30: 403K2020-12-15: 455K2020-12-31: 613K2021-01-15: 286K2021-01-29: 291K2021-02-12: 272K2021-02-26: 252K2021-03-15: 222K2021-03-31: 246K2021-04-15: 253K2021-04-30: 275K2021-05-14: 292K2021-05-28: 330K2021-06-15: 305K2021-06-30: 467K2021-07-15: 600K
    the 15 Jul 2021 report24 earlier reportsnormal: 298K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 13 Jan 2021Short interest and volume change

    had 613K shares sold short in the 31 Dec 2020 report, 1.1× the same report last year.

    Same report last year: 574K; its normal report is 363K.

    See the evidence
    This period
    613K (the 31 Dec 2020 report)
    Normal report (median of 24 earlier)
    363K
    Typical spread (median absolute deviation)
    37K
    How far from its usual level
    +4.5
    Same report last year
    574K
    History used
    1,098 days
    2019-12-31: 574K2020-01-15: 539K2020-01-31: 475K2020-02-14: 455K2020-02-28: 419K2020-03-13: 382K2020-03-31: 342K2020-04-15: 340K2020-04-30: 357K2020-05-15: 347K2020-05-29: 332K2020-06-15: 280K2020-06-30: 390K2020-07-15: 397K2020-07-31: 354K2020-08-14: 305K2020-08-31: 285K2020-09-15: 259K2020-09-30: 191K2020-10-15: 368K2020-10-30: 374K2020-11-13: 348K2020-11-30: 403K2020-12-15: 455K2020-12-31: 613K
    the 31 Dec 2020 report24 earlier reportsnormal: 363K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 22 Jul 2019Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['CPT']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    12653231
  20. 31 Oct 2017Lobbying record

    CARIS LIFE SCIENCES, INC.: new lobbying registration (SPLITOAK STRATEGIES LLC) (dated 19 Sep 2017)

  21. 29 Jul 2014Lobbying record

    CARIS LIFE SCIENCES, INC.: lobbying engagement terminated (THE MCMANUS GROUP) (dated 20 Jun 2014)

  22. 21 Jul 2014Lobbying record

    CARIS LIFE SCIENCES, INC.: lobbying engagement terminated (in-house) (dated 20 Jun 2014)

  23. 27 Mar 2014Lobbying record

    CARIS LIFE SCIENCES, INC.: new lobbying registration (THE MCMANUS GROUP) (dated 15 Feb 2014)

  24. 22 Mar 2011Lobbying record

    CARIS LIFE SCIENCES, INC.: new lobbying registration (in-house) (dated 21 Mar 2011)

Not listed: 19 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0002019410
Ticker
CAI
Domain
carislifesciences.com
Hq location
TX|IRVING|75039 (1 unverified)
Lobbying client
caris life sciences
Name
Caris Life Sciences, Inc.
Wikidata
Q50039478
  • Federal lobbying disclosures (LDA)5 records, 152 data points21 Mar 2011 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 54 data points30 Jun 2025 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)19 records23 May 2025 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)148 data points31 Dec 2022 to 2 Nov 2026
  • SEC Form 4 insider transactions10 records, 32 data points23 Jun 2025 to 23 Sep 2026
  • FINRA short interest (twice monthly)380 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2390 data points1 Aug 2018 to 20 Nov 2026